Smartwatch ECG AI Deal: AliveCor Plans Premature-Beat Checks for Apple Watch Only
Reported by Tech Times1 source ↓
AliveCor and PulseAI plan to add PulseAI rhythm analysis to the Kardia App for KardiaCare subscribers in the first half of 2027. Apple Watch is set to get premature ventricular contraction labels; three other named watches are limited to AFib and sinus-rhythm checks.
Key points
- The Kardia App integration is planned for KardiaCare subscribers in the first half of 2027
- Apple Watch is slated for four rhythm determinations and beat-by-beat PVC labels
- Galaxy Watch, Fitbit Sense and Withings ScanWatch are slated for AFib and sinus-rhythm checks
- The FDA clearance is for adults when prescribed or used under a physician’s care; over-the-counter use was not selected
- Pricing and a firm launch date were not announced
Sources
Details
The Apple Watch feature set listed by the companies includes sinus rhythm, atrial fibrillation, bradycardia and tachycardia determinations, plus beat-by-beat classification of PVCs. For Galaxy Watch, Fitbit Sense and ScanWatch, the release lists sinus rhythm and AFib determinations, noisy-recording detection and an average-beat calculation; it does not list PVC labels, bradycardia or tachycardia.
The FDA clearance letter, dated October 27, 2026, limits the software’s indication to adults when prescribed or used under a physician’s care and marks over-the-counter use as not selected. Tech Times reports that the partnership announcement did not address prescriptions. It also does not identify which Apple Watch models will be compatible.
Tech Times reports that the software analyzes Lead I ECG data and sends recordings to the cloud for automated analysis, with structured results returned to the connected app. The article says the release gives no price or firm launch date.
Written from coverage as of
Images
- Tech Times
Stocks in this story
Change since open: 20 Nov to 21 Nov 2026
Last refresh